| Active substance | erdafitinib |
| Holder | Janssen-Cilag NV |
| Status | Running |
| Indication | This compassionate use program (CUP) is intended to provide early access to erdafitinib for the adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harboring susceptible FGFR3 genetic alterations with disease progression during or following at least one line of programmed death PD-1 or PD-L1 inhibitor in the locally advanced unresectable or metastatic treatment setting. |
| Public documents | Approbation |
| Information for the patient | |
| Informed Consent | |
| Last update | 03/04/2024 |